These modified liposomes utilize exposed Rk1 glycosides to reduce plasma protein adhesion and bind to GLUT1 protein highly expressed in tumor cells, resulting in enhanced tumor accumulation and over 50% reduction in tumor volume compared to conventional formulations [117]. This evidence concerns the gene SLC2A1 and neoplasm.